
What’s Next for PrEP? Innovation, Choice, and the Challenge of Equitable Access.
Posted: October 29, 2026
At IDWeek 2026, held October 21–24 in Washinton, DC, I was struck by how far HIV prevention has advanced and how much work remains to ensure everyone can benefit from that progress.
Researchers presented new findings on long-acting injectable pre-exposure prophylaxis (PrEP), emerging prevention technologies, real-world implementation, and persistent barriers to access. With daily oral PrEP, injectable cabotegravir every two months, and twice-yearly injectable lenacapavir, we have more effective prevention options than ever before.
Yet one message stood out: Scientific innovation alone will not end the HIV epidemic. We must ensure these advances reach the people and communities who need them most.
For NMAC, this is both an opportunity and a call to action.
Long-Acting PrEP Is Transforming Prevention
Long-acting injectable PrEP is changing what HIV prevention can look like. By reducing the frequency of medication administration, these options may address challenges associated with daily pills, including adherence, privacy concerns, and stigma.
Several IDWeek presentations examined the early implementation of twice-yearly lenacapavir, including research from Duke University Hospital and multi-site healthcare networks.
These studies reflect an important shift from demonstrating that medications work in clinical trials to understanding how we deliver them successfully in everyday practice.
How quickly can someone start injectable PrEP? How do insurance requirements affect access? What infrastructure and workforce are needed to support injections and follow-up?
These questions will increasingly determine whether scientific advances translate into meaningful reductions in HIV infections.
Interest in PrEP Does Not Always Mean Access
One particularly compelling IDWeek study examined injectable PrEP access in an Ending the HIV Epidemic priority state.
Among 170 people prescribed injectable PrEP, approximately 41% did not receive an injection. Insurance-related barriers, including inadequate pharmacy benefits and prior authorization denials, were frequently reported.
These findings illustrate the disconnect between what medicine can offer and what healthcare systems deliver.
Someone may be interested in PrEP, have a prescription, and be ready to begin prevention, yet remain unable to access medication because of administrative or financial barriers.
A prescription that cannot be filled is not meaningful access.
As new prevention options become available, insurers, policymakers, manufacturers, healthcare systems, and community organizations must work together to eliminate unnecessary barriers. We cannot allow insurance design or administrative complexity to determine who benefits from scientific progress.
Equity and Persistence Must Be Central to Implementation
Several IDWeek studies examined real-world persistence with injectable cabotegravir and racial and ethnic differences in patients’ experiences. Other research explored PrEP uptake in communities with high HIV incidence among Black cisgender women.
Together, these presentations raise two important questions: Are we reaching people who have historically been underserved by HIV prevention? And are we creating systems that help them continue prevention on their own terms?
Starting PrEP is only the beginning. Transportation, clinic scheduling, insurance changes, medication availability, and competing life responsibilities can all affect continued use.
Missed appointments should not automatically be interpreted as a lack of motivation. They may reflect healthcare systems that are insufficiently responsive to people’s circumstances.
We need flexible, culturally responsive services, effective navigation, and meaningful community involvement in designing prevention programs.
Equity cannot be an outcome we hope to achieve after implementation. It must guide implementation from the beginning.
HIV Prevention Must Address the Whole Person
Other IDWeek presentations explored the relationship between PrEP, substance use, sexually transmitted infections, and hepatitis B, reinforcing the importance of a whole-person approach to HIV prevention.
People do not experience HIV vulnerability in isolation. Sexual health, mental health, substance use, housing stability, stigma, and economic circumstances frequently intersect.
Effective PrEP programs should connect people with comprehensive sexual health services, behavioral health support, substance use services, and other resources that address their broader needs.
We must also expand PrEP beyond traditional infectious diseases clinics into primary care, reproductive healthcare, community health centers, and other trusted settings.
The goal is not simply to increase prescriptions. It is to make prevention accessible, relevant, and sustainable in people’s lives.
From IDWeek to BHPS 2027: Turning Innovation Into Action
The findings presented at IDWeek provide a powerful foundation for conversations at NMAC’s 2027 Biomedical HIV Prevention Summit (BHPS), April 28–30 in Orlando, Florida.
Under the theme Future Forward: The Next Era of HIV Prevention, BHPS will bring together researchers, healthcare providers, policymakers, public health leaders, and community advocates to explore how scientific advances can translate into meaningful community impact.
The Summit will focus on the challenges highlighted at IDWeek: expanding equitable access to emerging prevention technologies, applying implementation science, strengthening the workforce, addressing policy and financing barriers, and integrating HIV prevention into whole-person healthcare.
Importantly, BHPS will also emphasize the leadership of communities and young people in shaping the future of prevention.
We have extraordinary biomedical tools, but their impact will depend on the people, partnerships, policies, and systems that make them accessible.
The next breakthrough in HIV prevention must be in implementation.
Moving Forward Together
IDWeek 2026 reminded us of the extraordinary progress we have made in HIV prevention. But the next generation of PrEP will be defined not simply by how long a medication lasts, but by whether its benefits reach everyone who needs them.
For NMAC, that means expanding prevention choices, removing barriers, investing in the workforce, and ensuring communities remain at the center of decision-making.
IDWeek 2026 showed us what is possible. 2027 Biomedical HIV Prevention Summit will challenge us to turn that possibility into action. We invite everyone committed to ending the HIV epidemic to join us in Orlando as we work to make the promise of prevention a reality for everyone.
Selected IDWeek 2026 Research
- Long-Acting Injectable PrEP: Interest vs. Access
- Early Real-World Adoption of Lenacapavir
- Real-World Persistence: PrEPFACTS Study
- Racial and Ethnic Differences in Injectable PrEP Experiences
- PrEP Uptake Among Black Cisgender Women
- Substance Use and PrEP Outcomes
- HPTN 103/PURPOSE 4
- PrEP Cost-Sharing and HIV Diagnoses